



## DNA Methylation in Cancer

Guest Editors:

**Prof. Dr. Patrizia Zavattari**

Department of Biomedical Sciences, Unit of Biology and Genetics, University of Cagliari, 09042 Cagliari, Italy

pzavattari@unica.it

**Dr. Eleonora Loi**

Department of Biomedical Sciences, Unit of Biology and Genetics, University of Cagliari, Cagliari, Italy

eleonora.loi@unica.it

**Dr. Sergio Alonso**

Program of Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain

salonsou@igt.p.cat

### Message from the Guest Editors


DNA methylation alterations underlie the carcinogenic process from its earliest stages. This is characterized by global losses of DNA methylation coupled with localized ectopic gains of DNA methylation at CpG islands, which are frequently associated with gene expression changes. A homeostatic balance between heterochromatin and euchromatin is essential to genomic stability. This Special Issue will give an overview of the various aspects that these epigenetic changes represent in cancer. Topics of interest will include but are not limited to the following: potential biomarkers for early detection and important prognostic and predictive markers to improve therapeutic interventions; the detection of these biomarkers through less invasive or noninvasive procedures; new therapeutic approaches based on epigenetic reprogramming; improved knowledge of the cellular processes affected by such early changes in the context of future functional studies.

Deadline for manuscript submissions:

**15 February 2022**



[mdpi.com/si/78160](https://mdpi.com/si/78160)



## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:**—free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed by the [Science Citation Index Expanded](#) (Web of Science) and [Biosis Previews](#), [Scopus](#) (2019 CiteScore: 3.4) and [other databases](#). Citations available in [PubMed](#), full-text archived in [PubMed Central](#).

**JCR Category Rank:** 37/244 (Q1) in 'Oncology'.

## Contact Us

---

*Cancers*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)